[Effects of Bone Marrow Mesenchymal Stem Cells Derived from Patients with Newly Diagnosed Acute Myeloid Leukemia on the Cell Proliferation, Cell Cycle and Immunophenotypes of HL-60 Cells]

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2019 Aug;27(4):1259-1264. doi: 10.19746/j.cnki.issn.1009-2137.2019.04.044.
[Article in Chinese]

Abstract

Objective: To explore the role of bone marrow microenvironment(niche) in the development of acute myeloid leukemia (AML) and the effect of AML patients-derived MSC on the proliferation, cell cycle and immuno-phenotypes of HL-60 cells.

Methods: The MSC derived from bone marrow of patients with newly diagnosed AML were isolated and co-cultured with HL-60 cells. The effect of MSC on proliferation of HL-60 cells was detected by using 3H-TdR incorporation method, the cell cycle and immunophenotypes of HL-60 cells were detected by flow cytometry.

Results: The results of 3H-TdR incorporation assay showed that both AML-MSCs and normal MSCs remarkably suppressed the HL-60 cell proliferation in a time- and dose-dependent manner. The results of cell cycle analysis demonstrated that AML MSCs and normal MSCs induced arrest of the HL-60 cells in G0/G1 phase. The results of immunophenotyping revealed that MSCs suppressed the expression of CD11a and CD154 on the surface of HL-60 cells. Moreover, AML MSCs exhibited increased inhibitory effects than that of normal MSCs. However, no remarkable effect of MSCs on CD54 expressions of HL-60 cells was observed in the current study.

Conclusion: AML-MSCs possess effects on HL-60 cell proliferation, cell cycle and immunophenotypes similiar to normal MSCs, but exhibited increased suppressive capacity on the expression of CD11a and CD154.

题目: 初诊急性髓系白血病患者来源的骨髓间充质干细胞调节HL-60细胞的增殖、细胞周期和免疫表型.

目的: 探讨急性髓系白血病(AML)患者的骨髓微环境在发病过程中的作用及AML患者间充质干细胞(MSC)对HL-60细胞的增殖、细胞周期和免疫表型的影响.

方法: 分离初诊AML患者骨髓MSC,将其和HL-60细胞共培养,以3H-TdR掺入法检测MSC对HL-60细胞增殖的影响,应用流式细胞术检测HL-60的细胞周期和免疫表型.

结果: 3H-TdR掺入法的结果表明,初诊AML患者骨髓MSC显著抑制HL-60增殖,并且具有良好的量效关系(r=0.998)。 细胞周期分析结果显示,MSC使HL-60细胞更多的阻滞在G0/G1期。免疫表型分析结果表明,与单独培养的HL-60细胞相比,与正常MSC和患者MSC共培养的HL-60细胞CD11a的阳性率均显著下降,分别为(50.80±10.41)% vs (36.23±8.82)%(P<0.05)和(50.80±10.41 )% vs (16.93±9.25)%(P<0.001),患者MSC共培养组和正常MSC共培养组之间也存在显著差异(16.93±9.25)% vs (36.23±8.82)%(P<0.001)。同样,与正常MSC和患者MSC共培养的HL-60细胞CD154表达也显著降低,分别为(65.67±11.91)% vs (39.85±12.11)%(P<0.01)和(65.67±11.91)% vs (17.18±9.29)%(P<0.001),且与患者MSC共培养组CD154表达降低更明显(39.85±12.11)% vs (17.18±9.29)%(P<0.05)。CD54的表达未见改变.

结论: 初诊的AML患者骨髓中存在的MSC具有与健康人骨髓MSC相似的调节HL-60增殖、细胞周期和免疫表型的能力,其抑制CD11a和CD154的能力更强于健康人骨髓MSC.

MeSH terms

  • Bone Marrow Cells
  • Cell Cycle
  • Cell Proliferation
  • HL-60 Cells
  • Humans
  • Immunophenotyping
  • Leukemia, Myeloid, Acute*
  • Mesenchymal Stem Cells*
  • Tumor Microenvironment